[go: up one dir, main page]

MA41251A - Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk - Google Patents

Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk

Info

Publication number
MA41251A
MA41251A MA041251A MA41251A MA41251A MA 41251 A MA41251 A MA 41251A MA 041251 A MA041251 A MA 041251A MA 41251 A MA41251 A MA 41251A MA 41251 A MA41251 A MA 41251A
Authority
MA
Morocco
Prior art keywords
thiéno
pyrrol
derivatives
erk inhibitors
erk
Prior art date
Application number
MA041251A
Other languages
English (en)
Other versions
MA41251B1 (fr
Inventor
Guillermo S Cortez
Sajan Joseph
Johnathan Alexander Mclean
William T Mcmillen
Michael John Rodriguez
Gaiying Zhao
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA41251A publication Critical patent/MA41251A/fr
Publication of MA41251B1 publication Critical patent/MA41251B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA41251A 2014-12-22 2015-12-16 Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk MA41251B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462095185P 2014-12-22 2014-12-22
PCT/US2015/065940 WO2016106029A1 (fr) 2014-12-22 2015-12-16 Dérivés de thiéno[2,3-c]pyrrol-4-one utilisés en tant qu'inhibiteurs de erk
EP15823869.1A EP3237423B1 (fr) 2014-12-22 2015-12-16 Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk

Publications (2)

Publication Number Publication Date
MA41251A true MA41251A (fr) 2017-11-01
MA41251B1 MA41251B1 (fr) 2019-09-30

Family

ID=55135525

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41251A MA41251B1 (fr) 2014-12-22 2015-12-16 Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk

Country Status (44)

Country Link
US (3) US9469652B2 (fr)
EP (1) EP3237423B1 (fr)
JP (1) JP6445701B2 (fr)
KR (1) KR101917972B1 (fr)
CN (1) CN107108648B (fr)
AR (1) AR102977A1 (fr)
AU (1) AU2015369983C1 (fr)
BR (1) BR112017011130A2 (fr)
CA (1) CA2966559C (fr)
CL (1) CL2017001514A1 (fr)
CO (1) CO2017005217A2 (fr)
CR (1) CR20170182A (fr)
CY (1) CY1121831T1 (fr)
DK (1) DK3237423T3 (fr)
DO (1) DOP2017000122A (fr)
EA (1) EA031659B1 (fr)
EC (1) ECSP17038500A (fr)
ES (1) ES2738406T3 (fr)
GT (1) GT201700134A (fr)
HR (1) HRP20191268T1 (fr)
HU (1) HUE045933T2 (fr)
IL (1) IL252065B (fr)
JO (1) JO3596B1 (fr)
LT (1) LT3237423T (fr)
MA (1) MA41251B1 (fr)
MD (1) MD3237423T2 (fr)
ME (1) ME03490B (fr)
MX (1) MX371206B (fr)
MY (1) MY178426A (fr)
NZ (1) NZ731531A (fr)
PE (1) PE20171043A1 (fr)
PH (1) PH12017501155B1 (fr)
PL (1) PL3237423T3 (fr)
PT (1) PT3237423T (fr)
RS (1) RS59015B1 (fr)
SG (1) SG11201704521SA (fr)
SI (1) SI3237423T1 (fr)
SV (1) SV2017005443A (fr)
TN (1) TN2017000233A1 (fr)
TR (1) TR201909887T4 (fr)
TW (1) TWI704151B (fr)
UA (1) UA119686C2 (fr)
WO (1) WO2016106029A1 (fr)
ZA (1) ZA201702786B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105636586B (zh) 2013-10-03 2018-05-29 库拉肿瘤学公司 Erk抑制剂及使用方法
WO2016106009A1 (fr) 2014-12-22 2016-06-30 Eli Lilly And Company Inhibiteurs d'erk
TWI704151B (zh) * 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑
MY204050A (en) 2015-10-21 2024-08-05 Otsuka Pharma Co Ltd Benzolactam compounds as protein kinase inhibitors
EP3478292A1 (fr) * 2016-06-29 2019-05-08 Eli Lilly and Company Combinaison d'un composé inhibiteur d'erk1/2 avec la gemcitabine ou avec la gemcitabine et nab-paclitaxel pour utilisation dans le traitement du cancer du pancréas
WO2018081204A1 (fr) * 2016-10-26 2018-05-03 Li George Y N-(5-((4-éthylpipérazine-1-yl)méthyl) pyridin-2-yl)-5-fluoro-4-(4-fluoro-1-isopropyl-2-méthyl-1h-benzo[d]imidazol-6-yl)pyrimidin-2-amine deutéré
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
JP7312171B2 (ja) 2017-11-24 2023-07-20 ヤンセン ファーマシューティカ エヌ．ベー． ピラゾロピリジノン化合物
AU2019253706A1 (en) * 2018-04-09 2020-11-26 G1 Therapeutics, Inc. Treatment of cancers having driving oncogenic mutations
SG11202011513RA (en) * 2018-05-22 2020-12-30 Js Innomed Holdings Ltd Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
SG11202106635WA (en) 2018-12-21 2021-07-29 Daiichi Sankyo Co Ltd Combination of antibody-drug conjugate and kinase inhibitor
US20220153750A1 (en) 2019-03-27 2022-05-19 Eli Lilly And Company Salts of 5,6-dihydro-4h-thieno[2,3-c]pyrrol-4-one compound as erk inhibitors
US20220213119A1 (en) 2019-03-28 2022-07-07 Jiangsu Hengrui Medicine Ca, Lid. Thienoheterocyclic derivative, preparation method therefor and medical use thereof
TW202102505A (zh) * 2019-03-29 2021-01-16 大陸商江蘇恆瑞醫藥股份有限公司 吡咯并雜環類衍生物、其製備方法及其在醫藥上的應用
WO2020231976A1 (fr) * 2019-05-16 2020-11-19 Eli Lilly And Company Triple association d'un inhibiteur d'erk1/2, d'un inhibiteur de braf et d'un inhibiteur de l'egfr, destinée à être utilisée dans le traitement du cancer colorectal positif pour la mutation v600e de braf
CN112457326B (zh) * 2019-09-06 2022-02-15 上海凌达生物医药有限公司 一类芳香杂环并内酰胺类化合物、制备方法和用途
CA3160899C (fr) * 2019-12-06 2024-04-16 Medshine Discovery Inc. Compose spiro servant d'inhibiteur d'erk et son application
CN110950876B (zh) * 2019-12-10 2021-08-17 上海凌达生物医药有限公司 一类呋喃并内酰胺类化合物、制备方法和用途
WO2021216777A1 (fr) * 2020-04-21 2021-10-28 The Trustees Of The Stevens Institute Of Technology Inhibiteurs d'erk pour thérapie anticancéreuse
CN114315837B (zh) * 2020-09-29 2023-06-16 江苏恒瑞医药股份有限公司 一种erk抑制剂的结晶形式及其制备方法
US20230331731A1 (en) * 2020-09-29 2023-10-19 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Crystal form of pyrrolo heterocyclic derivative and preparation method therefor
JP7702752B2 (ja) * 2021-06-28 2025-07-04 徳昇済医薬（無錫）有限公司 チアゾール－ラクタム－スピロ複素環化合物及びその適用
BR112023027454A2 (pt) * 2021-06-28 2024-03-12 D3 Bio Wuxi Co Ltd Composto, uso de um composto, medicamento, e, invenção de produto, processo, sistema, kit ou uso
TW202332448A (zh) * 2021-11-15 2023-08-16 美商艾瑞斯卡公司 噻吩ulk1/2抑制劑及其用途
WO2023137297A2 (fr) * 2022-01-11 2023-07-20 Suvalent Therapeutics, Inc. Inhibiteurs de 5,6-dihydro-4h-thieno[2,3-c]pyrrole sumo et leurs utilisations
US20240352029A1 (en) * 2023-04-14 2024-10-24 Prelude Therapeutics Incorporated CDK Inhibitors And Their Use As Pharmaceuticals
WO2024229406A1 (fr) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Polythérapie pour une maladie ou un trouble lié à ras
WO2025034702A1 (fr) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 destiné à être utilisé dans le traitement d'une maladie ou d'un trouble lié à une protéine ras
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025240847A1 (fr) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025255438A1 (fr) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4023048A1 (de) * 1990-07-20 1992-01-23 Basf Ag Dicarbonsaeureimide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
CA2422367C (fr) * 2000-09-15 2010-05-18 Vertex Pharmaceuticals Incorporated Composes de pyrazole pouvant etre utilises comme inhibiteurs de la proteine kinase
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1487856B1 (fr) 2002-03-04 2010-07-28 Imclone LLC Anticorps humains specifiques de kdr et leurs utilisations
AU2003295396B2 (en) * 2002-11-04 2009-02-26 Vertex Pharmaceuticals Incorporated Heteroaryl-pyramidine derivatives as JAK inhibitors
UA80571C2 (en) 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
CA2628474A1 (fr) * 2005-11-03 2007-05-10 Sgx Pharmaceuticals, Inc. Modulateurs de kinase de type pyrimidinylthiophene
JP5731976B2 (ja) 2008-08-20 2015-06-10 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 置換ピリジン誘導体および置換ピリミジン誘導体ならびにそれらのウイルス感染の治療における使用
EP2346860B1 (fr) * 2008-10-08 2012-09-19 Bristol-Myers Squibb Company Antagonistes de récepteur d'hormone concentrant la mélanine 1 de type pyrrolone
PA8852901A1 (es) * 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
US8975260B2 (en) * 2010-09-01 2015-03-10 Genetech, Inc Pyridazinones, method of making, and method of use thereof
AR087107A1 (es) 2011-07-27 2014-02-12 Lilly Co Eli Compuesto inhibidor de la señalizacion de la trayectoria notch
ES2857649T3 (es) * 2012-03-01 2021-09-29 Array Biopharma Inc Inhibidores de serina/treonina cinasa
AR090151A1 (es) 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
BR112015006363A2 (pt) * 2012-09-28 2017-08-08 Boehringer Ingelheim Int combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r
TWI704151B (zh) * 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑
WO2016106009A1 (fr) * 2014-12-22 2016-06-30 Eli Lilly And Company Inhibiteurs d'erk

Also Published As

Publication number Publication date
AU2015369983A1 (en) 2017-05-25
TN2017000233A1 (en) 2018-10-19
TR201909887T4 (tr) 2019-07-22
KR20170083145A (ko) 2017-07-17
PT3237423T (pt) 2019-08-21
JO3596B1 (ar) 2020-07-05
EA201791133A1 (ru) 2017-10-31
US9526733B1 (en) 2016-12-27
UA119686C2 (uk) 2019-07-25
DOP2017000122A (es) 2017-06-15
CA2966559C (fr) 2019-06-18
EP3237423B1 (fr) 2019-06-05
US20160176896A1 (en) 2016-06-23
SV2017005443A (es) 2018-08-27
JP2017538768A (ja) 2017-12-28
MX371206B (es) 2020-01-22
PH12017501155A1 (en) 2017-11-27
PH12017501155B1 (en) 2022-03-25
EP3237423A1 (fr) 2017-11-01
USRE48635E1 (en) 2021-07-13
US20160375030A1 (en) 2016-12-29
BR112017011130A2 (pt) 2017-12-26
ZA201702786B (en) 2019-02-27
KR101917972B1 (ko) 2018-11-12
PE20171043A1 (es) 2017-07-19
MD3237423T2 (ro) 2019-11-30
GT201700134A (es) 2018-11-23
CY1121831T1 (el) 2020-07-31
IL252065A0 (en) 2017-07-31
DK3237423T3 (da) 2019-07-22
ME03490B (fr) 2020-01-20
MY178426A (en) 2020-10-13
IL252065B (en) 2020-08-31
CR20170182A (es) 2017-06-21
MX2017008242A (es) 2017-10-06
AU2015369983C1 (en) 2019-02-21
CA2966559A1 (fr) 2016-06-30
CL2017001514A1 (es) 2018-02-09
HRP20191268T1 (hr) 2019-11-01
MA41251B1 (fr) 2019-09-30
NZ731531A (en) 2018-12-21
CN107108648B (zh) 2019-07-12
US9469652B2 (en) 2016-10-18
CO2017005217A2 (es) 2017-09-20
AU2015369983B2 (en) 2018-08-23
JP6445701B2 (ja) 2018-12-26
HUE045933T2 (hu) 2020-01-28
RS59015B1 (sr) 2019-08-30
TW201632530A (zh) 2016-09-16
CN107108648A (zh) 2017-08-29
SG11201704521SA (en) 2017-07-28
EA031659B1 (ru) 2019-02-28
AR102977A1 (es) 2017-04-05
ES2738406T3 (es) 2020-01-22
SI3237423T1 (sl) 2019-08-30
LT3237423T (lt) 2019-08-26
ECSP17038500A (es) 2017-12-01
PL3237423T3 (pl) 2020-01-31
TWI704151B (zh) 2020-09-11
WO2016106029A1 (fr) 2016-06-30

Similar Documents

Publication Publication Date Title
MA41251A (fr) Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk
MA43753A (fr) Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu
MA45591A (fr) Dérivés de 1,3-dihydroxy-phényle utiles comme immunomodulateurs
IL256898A (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
IL256265B (en) 3-tetrazolyl-benzene-2,1-disulfonamide derivatives as metallo-beta-lactamase inhibitors
DK3324977T3 (da) Benzodiazepinderivater som rsv-inhibitorer
LT3190113T (lt) Pirolopirimidino junginiai, naudotini kaip tlr7 agonistai
LT3371190T (lt) Heterocikliniai junginiai, kaip pi3k-gama inhibitoriai
MA42597A (fr) 2-amino-3-fluoro-3-(fluorométhyl)-6-méthyl-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
DK3478681T3 (da) 1h-pyrazolo[4,3-b]pyridiner som pde1-inhibitorer
IL252089B (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
LT3288944T (lt) Imidazopirazinonai, kaip pde1 inhibitoriai
EP3380475A4 (fr) Dérivés d'octahydropyrrolo [3, 4-c
MA40941A (fr) 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
SG11201610770PA (en) Quinolizinone derivatives as pi3k inhibitors
SG11201701378WA (en) Pyrido-oxazinone derivatives as tnap inhibitors
LT3233862T (lt) Imidazopiridazino dariniai, kaip pi3kbeta slopikliai
EP3215552A4 (fr) Dérivés de 1,3-propanediol
EP3277603A4 (fr) Support de cuisse de dinde
MA41641A (fr) Dérivés de tétrahydropyranylbenzamide
DK3194408T3 (da) Tetrahydropyrrolo[3,4-d][1,3]thiazin-derivat som bace-inhibitor
MA42604A (fr) 2-amino-7a-phényl-3,4,4a,5,7,7a-hexahydrofuro[3,4-b]pyridines comme inhibiteurs de bace1
HUE038944T2 (hu) Tiokromeno[2,3-c]kinolin-12-on származékok és topoizomeráz inhibitorként való alkalmazásuk
HK1246289A1 (en) 3-tetrazolyl-benzene-1,2-disulfonamide derivatives as metallo-beta-lactamase inhibitors
HK1262303A1 (en) Tdo2 inhibitors